Physician profile
Suneetha Amara
NPI 1699088096
$1,354.51
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $915 · 2020: $439.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $174.96 | 2019-2020 | |
| Lilly USA, LLC | $161.68 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $126.33 | 2019-2020 | |
| Incyte Corporation | $111.30 | 2019 | |
| Novartis Pharmaceuticals Corporation | $107.79 | 2019-2020 | |
| Astellas Pharma US INC | $95.50 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $63.28 | 2019 | |
| Alexion Pharmaceuticals, INC. | $54.26 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.77 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.70 | 2019-2020 | |
| Agios Pharmaceuticals, INC. | $34.50 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $32.86 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $27.72 | 2019-2020 | |
| Btg International INC. | $25.46 | 2019 | |
| Genentech USA, INC. | $24.69 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Secura Bio, INC. | $21.84 | 2019-2020 | |
| Celgene Corporation | $21.67 | 2020 | |
| Coherus Oncology, INC. | $20.04 | 2020 | |
| Eisai INC. | $19.25 | 2020 | |
| Abbvie INC. | $16.94 | 2020 | |
| Daiichi Sankyo INC. | $15.71 | 2020 | |
| Pfizer INC. | $14.59 | 2020 | |
| Glaxosmithkline, LLC. | $14.04 | 2020 | |
| Seagen INC. | $13.84 | 2019 | |
| Karyopharm Therapeutics INC. | $13.46 | 2020 | |
| Shire North American Group INC | $13.37 | 2019 | |
| Kyowa Kirin, INC. | $11.14 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.08 | 2020 | |
| Janssen Pharmaceuticals, INC | $10.89 | 2019 | |
| Merck Sharp & Dohme LLC | $10.85 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suneetha Amara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.